Originally published In Press as doi:10.1074/jbc.M002541200 on April 20, 2000
J. Biol. Chem., Vol. 275, Issue 28, 21324-21330, July 14, 2000
Absence of ACAT-1 Attenuates Atherosclerosis but Causes Dry Eye
and Cutaneous Xanthomatosis in Mice with Congenital Hyperlipidemia*
Hiroaki
Yagyu
§,
Tetsuya
Kitamine
§,
Jun-ichi
Osuga
,
Ryu-ichi
Tozawa
,
Zhong
Chen
,
Yuichi
Kaji¶,
Teruaki
Oka
,
Stéphane
Perrey
,
Yoshiaki
Tamura
,
Ken
Ohashi
,
Hiroaki
Okazaki
,
Naoya
Yahagi
,
Futoshi
Shionoiri
,
Yoko
Iizuka
,
Kenji
Harada
,
Hitoshi
Shimano
,
Hidetoshi
Yamashita¶**,
Takanari
Gotoda
,
Nobuhiro
Yamada

, and
Shun
Ishibashi
§§
From the Departments of
Metabolic Diseases,
¶ Ophthalmology, and
Pathology, Faculty of Medicine,
University of Tokyo, Hongo, Tokyo 113-8655, Japan
Received for publication, March 26, 2000, and in revised form, April 17, 2000
 |
ABSTRACT |
Acyl-CoA:cholesterol acyltransferase (ACAT)
catalyzes esterification of cellular cholesterol. To investigate the
role of ACAT-1 in atherosclerosis, we have generated ACAT-1 null
(ACAT-1
/
) mice. ACAT activities were present in the liver and
intestine but were completely absent in adrenal, testes, ovaries, and
peritoneal macrophages in our ACAT-1
/
mice. The ACAT-1
/
mice
had decreased openings of the eyes because of atrophy of the meibomian
glands, a modified form of sebaceous glands normally expressing high
ACAT activities. This phenotype is similar to dry eye syndrome in
humans. To determine the role of ACAT-1 in atherogenesis, we crossed
the ACAT-1
/
mice with mice lacking apolipoprotein (apo) E or the low density lipoprotein receptor (LDLR), hyperlipidemic models susceptible to atherosclerosis. High fat feeding resulted in extensive cutaneous xanthomatosis with loss of hair in both ACAT-1
/
:apo E
/
and ACAT-1
/
:LDLR
/
mice. Free cholesterol content was significantly increased in their skin. Aortic fatty streak lesion size
as well as cholesteryl ester content were moderately reduced in both
double mutant mice compared with their respective controls. These
results indicate that the local inhibition of ACAT activity in tissue
macrophages is protective against cholesteryl ester accumulation but
causes cutaneous xanthomatosis in mice that lack apo E or LDLR.
 |
INTRODUCTION |
Esterification of intracellular cholesterol is catalyzed by a
microsomal enzyme, acyl-CoA:cholesterol acyltransferase (ACAT; EC
2.3.1.26) (1, 2).1 In the
liver and small intestine, cholesterol is esterified by ACAT and
incorporated into apolipoprotein (apo) B-containing lipoproteins, which
are subsequently secreted into circulation. After lipolytic conversion,
these lipoproteins are taken up by the cells of various organs, where
their cholesteryl esters (CE) are hydrolyzed in lysosomes to liberate
free cholesterol (FC), which is re-esterified by ACAT again for storage
in cytoplasmic lipid droplets.
Two ACAT genes have been identified in mammals (3-6). ACAT-1, which
was originally cloned from a macrophage cDNA library (3), is
ubiquitously expressed. In particular, it is highly expressed in
preputial glands, steroidogenic organs, sebaceous glands, and
macrophages (7-9). However, its physiological roles in each organ are
yet to be determined. ACAT-1 is also expressed in macrophage-derived
foam cells in human atherosclerotic lesions (10), where it is thought
to mediate foam cell formation, an initial event of atherosclerosis.
Therefore, it is plausible that inhibition of ACAT in the arterial wall
cells exerts a protective effect against atherosclerosis. In contrast,
ACAT-2 is expressed only in the liver and small intestine and is
conceivably involved in lipoprotein assembly and secretion (4-6).
Consistently, ACAT activities were eliminated from the macrophages and
adrenal glands but not from the liver in ACAT-1 knockout mice reported
by Meiner et al. (11, 12).
To further explore the other unknown functions of ACAT-1 and to
determine whether the elimination of ACAT-1 has an anti-atherogenic effect, we have generated ACAT-1 knockout mice by homologous
recombination with a targeting vector that is designed to delete the
first membrane spanning region plus a serine 268 that is crucial for
the catalytic activity of ACAT-1 (13) and crossed these animals with
hyperlipidemic mutant mice, apo E-deficient (apo E
/
) (14), and the
low density lipoprotein (LDL) receptor-deficient (LDLR
/
) mice (15),
which are susceptible to atherosclerosis.
 |
MATERIALS AND METHODS |
General Methods--
Standard molecular biology techniques were
used (16). Before sacrifice, mice were anesthetized with pentobarbital.
Sick mice were euthanized. The current experiments were performed in accord with institutional guidelines for animal experiments at the
University of Tokyo.
Diets--
Three diets were used: (i) a normal chow diet (MF
diet from Oriental Yeast Co., Tokyo) that contained 5.6% (w/w) fat
with 0.09% (w/w) cholesterol; (ii) a high fat diet A: MF diet
containing 0.15% (w/w) cholesterol and 15% (w/w) butter (essentially
similar to Western style diet (17)); (iii) a high fat diet B: MF diet containing 1.25% (w/w) cholesterol, 15% (w/w) cocoa butter, 0.5% (w/w) cholic acid essentially as described by Paigen et al.
(18, 19). Preliminary experiments have shown that feeding with high fat
diet B made many of the apo E
/
mice sick probably because of
extreme hyperlipidemia irrespective of the presence of the ACAT-1 gene.
On the other hand, LDLR
/
mice developed only a minimal lesions in 8 weeks when fed with high fat diet A. Accordingly, two different high
fat diets were used to analyze ACAT-1
/
:apo E
/
or
ACAT-1
/
:LDLR
/
double knockout mice.
Generation of ACAT-1 Knockout Mice--
A fragment (1623 base
pairs) of mouse ACAT-1 cDNA was amplified by polymerase chain
reaction using primers that were designed based on reported sequences
of human ACAT-1 cDNA (sense primer, 5'-ATGGTGGGTGAAGAGAAGATGTCTCTAAGAA-3', and antisense primer,
5'-AAACACGTAACGACAAGTCCAGGAACGTGG-3') (3) and was subcloned into pCRII
(Invitrogen). After labeling with 32P using the Megaprime
DNA labeling system (Amersham Pharmacia Biotech) and
[
-32P]dCTP (Amersham Pharmacia Biotech), the cDNA
fragment was used as a probe to screen a 129/Sv mouse genomic library,
which had been constructed in Lambda Dash II (Stratagene) as described
previously (20, 21). One genomic clone coding the 5' side of ACAT-1
cDNA was sequenced. A 1-kb fragment in intron 5 was amplified by
polymerase chain reaction using the following primers: sense primer,
5'-CGCTCGAGTTCAGTCCTCATTAATGAG-3' and antisense primer,
5'-CGCTCGAGGTAAATTGTTCTGATGTGG-3', and used as the short arm (22).
Another 13-kb genomic clone that contained a fragment of the ACAT gene
spanning intron 11 to exon 16 was directly used as the long arm.
A replacement-type targeting vector was constructed by ligating the
short and long arms into the XhoI and NotI sites,
respectively, of the vector pPolIIshort-neobpA-HSVTK as described
previously (15, 21) (see Fig. 1A). A 4-kb piece of the gene
that contained exons 6-10, which encoded the first membrane spanning
domain (23) and serine 268 that is crucial for the enzyme activity
(13), was replaced by a neomycin-resistant cassette. Theoretically,
homologous recombination would produce a totally inactive enzyme.
After digestion with SalI, the vector was electroporated
into JH1 embryonic stem cells. Targeted clones that had been selected in the presence of G418 and 1-(2-deoxy,
2-fluoro-
-D-arabinofuranosyl)-5 iodouracil were
identified by polymerase chain reaction using the following primers:
5'-TCTGGAGAAAAATGCAGGCTTCTTAC-3' and 5'-GATTGGGAAGACAATAGCAGGCATGC-3' (see Fig. 1A). Homologous recombination was verified by
Southern blot analysis after digestion with EcoRI using a
fragment that was upstream of the short arm as a probe (probe B; see
Fig. 1A). Targeted embryonic stem clones were injected into
the C57BL/6J blastocysts, yielding four lines of chimeric mice that
transmitted the disrupted allele through the germline. All experiments
reported here were performed with 129/Sv-C57BL/6J hybrid descendants
(F1 and subsequent generations) of these animals. For genotyping, tail
DNA was digested with BamHI and subjected to Southern blot analyses using probe A (see Fig. 1A).
Breeding Experiments--
ACAT-1+/
mice were cross-bred to apo
E
/
or LDLR
/
mice to produce mice that were heterozygous for the
disrupted alleles of both ACAT-1 and either apo E or the LDL receptor
loci. The intercross of these animals was performed to produce
ACAT-1+/
:apo E
/
and ACAT-1+/
:LDLR
/
. Brother-sister mating
of ACAT-1+/
:apo E
/
or ACAT-1+/
:LDLR
/
mice was performed to
produce a set of apo E-deficient mice (ACAT-1+/+:apo E
/
,
ACAT-1+/
:apo E
/
, and ACAT-1
/
:apo E
/
) or a set of the LDL
receptor-deficient mice (ACAT-1+/+:LDLR
/
, ACAT-1+/
:LDLR
/
, and
ACAT-1
/
:LDLR
/
), respectively. Littermates were used as
controls. Therefore, genetic background of these animals were mixed:
50% C57BL/6J and 50% 129/Sv.
Preparation of Peritoneal Macrophages--
Peritoneal
macrophages were prepared as described previously (17).
Northern Blot Analyses--
Total RNA was isolated from cultured
peritoneal macrophages by using TRIZOL reagent (Life Technologies,
Inc.). 10 µg of total RNA was subjected to electrophoresis in 1%
agarose gel containing formamide and transferred to a nylon
filter (Hybond N, Amersham Pharmacia Biotech). cDNA probes (the
1623-base pair coding region of ACAT-1 and
-actin) were radiolabeled
with [
-32P]dCTP. After prehybridization for 2 h,
blots were hybridized in RapidhybR buffer (Amersham
Pharmacia Biotech) with indicated probes for 1 h at 65 °C.
Immunoblot Analyses--
cDNA fragment encoding N-terminal
125 amino acids of ACAT-1 was amplified by polymerase chain reaction
using primers (sense primer, 5'-GAGCATATGTCACTAAGAAACCGGCTGTCA-3';
antisense primer, 5'-TTCGGATCCTTAGTCTAAAAGAGACTGCCT-3') and cDNA
pool made from mouse peritoneal macrophages and subcloned into the
expression vector PW6A (24). After transformation, Escherichia
coli, BL21(DE3), were grown in LB medium in the presence of
isopropyl-
-D-thiogalactopyranoside. The cells were
disrupted by sonication and centrifuged to remove cellular debris. The
recombinant ACAT-1 peptide was purified by chromatography using SP
Sepharose FF column followed by Superdex 75 columns. ACAT-1
/
mice
were immunized with the purified recombinant ACAT-1 peptide. Standard
technique was used to generate a monoclonal antibody (25).
Peritoneal macrophages (1 × 107 cells) were
resuspended in 100 µl of buffer A (50 mM Tris-HCl, pH
7.8, 5 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride) containing 5% SDS. After an overnight incubation at 4 °C,
50 µg of protein was subjected to SDS/polyacrylamide gel electrophoresis. After transfer to a nitrocellulose membrane, immunoblot was performed using an ECL kit (Amersham Pharmacia Biotech)
with anti-mouse IgG (Amersham Pharmacia Biotech) as the secondary antibody.
Plasma Lipoprotein Analyses--
After a 16-h fast, blood was
collected from the retro-orbital venous plexus into tubes containing
EDTA. Plasma levels of total cholesterol (TC) and triglycerides (TG)
were determined enzymatically using kits (Determiner TC555 and
Determiner TG555, Kyowa Medex). Lipoproteins were fractionated by high
performance chromatography (HPLC), and the cholesterol contents in high
density lipoprotein fraction (HDL-C) were determined as described
(17).
Tissue and Cellular Lipids--
Lipids were extracted from
tissues by the method of Folch et al. (26). TC and FC were
determined by fluorometric microassay according to a modified method of
Heider and Boyett (27) with the exception that 0.01% (v/v) Triton
X-100 was used instead of Carbowax-600.
Assay of ACAT Activity--
Tissue was homogenized in buffer B
(0.25 M sucrose, 1 mM EDTA, 2 µg/ml
leupeptin, and 50 mM Tris-HCl, pH 7.0) and centrifuged at
107,000 × g for 60 min at 4 °C. The pellets were
resuspended and used for the assay. ACAT activity in microsomes or cell
homogenates was determined by the rate of incorporation of
[14C]oleoyl-CoA into the CE fraction according to
Billheimer et al. with minor modifications (28, 29).
Histology--
Tissues were fixed with neutral-buffered
formalin, embedded in paraffin, and stained with hematoxylin and eosin.
The aortic cross-sectional lesion area was evaluated according to a
modified method of Paigen et al. (17, 30). In brief, the
hearts were perfused with saline containing 4% (w/v) formalin and
fixed for more than 48 h in the same solution. The basal half of
the hearts was embedded in Tissue-Tek OCT compound (Miles, Inc.), and
the serial sections were captured using Cryostat microtome (6-µm
thick) as described (31). Four sections, each separated by 60 µm,
were used to evaluate the lesions: two at the end of the aortic sinus and two at the junctional site of sinus and ascending aorta. The sections were stained with Oil Red O and counter-stained with hematoxylin.
Statistics--
Data are represented as the means ± S.D.
Student's t test and analysis of variance were used to
compare the mean values between two and three groups, respectively.
 |
RESULTS |
Tissue-specific Role of ACAT-1--
A replacement-type vector was
used to generate chimeric mice (Fig.
1A). Heterozygous ACAT-1
knockout mice (ACAT-1+/
) born by these chimera, which were viable and
fertile, were intercrossed to obtain homozygous ACAT-1 knockout mice
(ACAT-1
/
). Wild type, heterozygotes, and homozygotes were born in
accordance with Mendelian fashion (+/+:+/
:
/
= 17:40:19,
2 = 0.16; p = 0.92) (Fig.
1B).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Targeted disruption of the ACAT-1 gene.
A, a map of the ACAT-1 locus, together with the sequence
replacement gene-targeting vector and the targeted ACAT-1 allele. The
gene targeting event replaced a 4-kb fragment containing the first
transmembrane domain and a conserved serine with a cassette containing
a neomycin-resistance gene (neor) driven by the RNA
polymerase II promoter. Two copies of herpes simplex virus thymidine
kinase (HSV-TK) expression cassette were used as a negative
selection marker. Gene-targeting events were verified by Southern blot
analyses using EcoRI and probe B for embryonic stem cell DNA
and BamHI and probe A for tail DNA. B, Southern
blot of BamHI fragment in the targeted allele is 7 kb
versus 10 kb for the wild-type allele when hybridized with
probe A. DNA was isolated from tails of offspring of heterozygous
matings. C, Northern blot analyses. 10 µg of total RNA was
isolated from peritoneal macrophages in culture and subjected to
Northern blot analyses. Two probes were used: cDNA fragment
containing the entire coding region of ACAT-1 (1623 base pairs) and
-actin as a reference. Three major transcripts are indicated.
D, immnunoblot analyses. Peritoneal macrophages were
isolated, and 50 µg of cellular protein was subjected to
SDS/polyacrylamide gel electrophoresis. After transfer to a
nitrocellulose membrane, immunoblot was performed using an ECL kit with
the antibody against a recombinant peptide encoding N-terminal 125 amino acids of ACAT-1 and anti-mouse IgG as the secondary
antibody.
|
|
To determine whether the expression of the ACAT-1 gene was ablated, we
performed Northern blot analyses (Fig. 1C). Although three
major mRNA transcripts (9.0, 4.6, and 3.5 kb) were detectable in
wild-type macrophages, adrenal glands, ovaries, and testes, no bands
were detectable in these organs from ACAT-1
/
mice. Approximately
one-half of the amounts of the three transcripts were expressed by the
cells from ACAT-1+/
mice. Consistent with the Northern blot results,
immunoblot analyses revealed no proteins that were immunoreactive with
an antibody raised against recombinant mouse ACAT-1 in the peritoneal
macrophages (Fig. 1D), adrenal glands, ovaries, and testes.
Therefore, it is reasonable to conclude that our ACAT-1
/
mice were
virtually null for ACAT-1.
Table I compares ACAT activities in
microsome fractions prepared from the liver, small intestine, adrenal
glands, testes, and ovaries, between the wild-type and ACAT-1
/
mice. In ACAT-1
/
mice, ACAT activity was barely detectable in the
adrenal glands, testes, and ovaries that normally express substantial
ACAT activity in the wild-type mice. In contrast to these steroidogenic
organs, the liver and small intestine from the ACAT-1
/
mice
expressed ACAT activities similar to those from wild-type mice.
View this table:
[in this window]
[in a new window]
|
Table I
Microsomal ACAT activities in various organs of wild-type and
ACAT-1 / mice
Microsome fractions were prepared from the indicated organs of
wild-type (+/+) and ACAT-1 / ( / ) mice aged 3 months. ACAT
activities were measured as described under "Materials and
Methods."
|
|
Atrophy of Meibomian Gland--
ACAT-1
/
mice were grossly
normal except that they had narrow eye fissures and lipid-depleted
adrenal glands. Abnormal facial expression was noted around the weaning
age (3-4 weeks) in almost all ACAT-1
/
mice (Fig.
2). Pathological examination of the eye balls and adnexa revealed that ACAT-1
/
mice had atrophic
acinar cells in the meibomian glands (Fig. 2). Upon bio-microscopic
examination, fine punctate stripping of the corneal epithelium was
observed. No other abnormalities were found in conjunctiva, cornea,
retina, or Harderian glands. Lipids in adrenal cortex were depleted in ACAT-1
/
mice (data not shown).

View larger version (104K):
[in this window]
[in a new window]
|
Fig. 2.
Facial appearance and histology of meibomian
glands of wild-type (+/+) and ACAT-1 / ( / ) mice. Facial
appearance (A, +/+; B, / ) and histology of
meibomian glands (C, +/+; D, / ) are shown.
Tarsus was prepared from eyelids and used for histological examination
(hematoxylin and eosin staining). The mice were females aged 5 months.
Note the narrow eye fissures and atrophic meibomian glands in
ACAT-1 / mice.
|
|
We measured FC and CE contents in steroidogenic organs whose ACAT
activities were markedly reduced in ACAT-1
/
mice and meibomian glands that exhibited remarkable acinar cell shrinkage in ACAT-1
/
mice (Fig. 3). In wild-type mice, most of
cholesterol was stored in its esterified form in adrenal glands,
ovaries, and meibomian glands. CE contents of these organs were
markedly reduced to a base-line level in ACAT-1
/
mice.
Interestingly, FC content was increased only in the meibomian glands of
ACAT-1
/
mice. There were virtually no differences in CE content of
testes between wild-type and ACAT-1
/
mice.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
FC and CE contents of adrenal glands, testes,
ovaries and meibomian glands. Open bars represent FC,
and closed bars represent CE. Lipids were extracted by
Folch's method and quantitated by the fluorometric assay. Three mice
aged 5 months were used. *, p < 0.01; **,
p < 0.001 versus +/+. Significant reduction
in CE was noted in the adrenals, ovaries, and meibomian glands. FC was
increased only in the meibomian glands of ACAT-1 / mice.
|
|
Massive Cutaneous Xanthomatosis and Alopecia in ACAT-1
/
Mice
Lacking apo E or the LDL Receptor--
To determine whether
hyperlipidemia affects the phenotypes of ACAT-1
/
mice, we generated
mice lacking both ACAT-1 and either apo E (ACAT-1
/
:apo E
/
) or
LDL receptor (ACAT-1
/
:LDLR
/
) by cross-breeding and used their
littermates as controls. Although the inactivation of the ACAT-1 gene
did not have a significant effect on the lipoprotein profiles in apo
E
/
mice, it slightly increased intermediate density lipoprotein/LDL
cholesterol levels in LDLR
/
mice (Table
II). These hyperlipidemic mice lacking the ACAT gene developed skin lesions upon aging (Fig.
4). Even on a normal chow diet, about
20% of ACAT-1
/
:apo E
/
mice developed skin lesions by the age
of 6 months (Fig. 4C). Typically, hair was lost, and skin
became rough and thick. In contrast, ACAT-1
/
:LDLR
/
mice did not
develop obvious skin lesions, at least by the age of 6 months, as long
as they were maintained on a normal chow diet.
View this table:
[in this window]
[in a new window]
|
Table II
Effects of the high fat diet feeding on the plasma lipid levels of
ACAT-1 / mice lacking either apo E or LDL receptor
At the age of 3 months, apo E-deficient mice were fed high fat diet A,
and LDL receptor-deficient mice were fed high fat diet B. Blood was
taken before and after feeding for 8 weeks. HDL-C was determined by
HPLC using pooled plasma. TC, TG, and HDL-C are in mg/dl. Data
represent the means ± S.D.
|
|

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 4.
Cutaneous xanthomatosis and alopecia in
ACAT-1-deficient mice that also lacked either apo E or the LDL
receptor. No apparent skin lesions were observed in ACAT-1+/+:apo
E / (A) and ACAT-1+/+:LDLR / mice (B).
ACAT-1 / :apoE / (C) and ACAT-1 / :LDLR / mice
(D) developed generalized alopecia with scaly thickened
skin. ACAT-1+/+:apo E / and ACAT-1 / :apo E / mice were
7-month-old males fed a normal chow diet. ACAT-1+/+:LDLR / and
ACAT-1 / :LDLR / mice were 5-month-old females fed the high fat
diet B for 8 weeks.
|
|
When ACAT-1
/
:apo E
/
and ACAT-1
/
:LDLR
/
mice were fed
high fat diets A and B, respectively, both mice developed more pronounced hypercholesterolemia (Table II) and more extensive skin
lesions (Fig. 4D). Compared with ACAT-1+/+:apo E
/
mice, ACAT-1
/
:apo E
/
mice had a 42% decrease in very
LDL/intermediate density lipoprotein-cholesterol levels. There was no
difference in the plasma lipoprotein profiles between
ACAT-1+/+:LDLR
/
and ACAT-1
/
:LDLR
/
mice, whereas very
LDL/intermediate density lipoprotein/LDL-cholesterol levels were
increased in ACAT-1+/
:LDLR
/
mice by 22%.
Microscopic examination revealed extensive infiltration of
macrophages throughout the entire dermal layer of
ACAT-1
/
:apoE
/
and ACAT-1
/
:LDLR
/
mice fed the high
fat diets (Fig. 5, C and D). Many macrophages exhibited foamy appearance with
multiple nuclei similar to the Touton type giant cells (Fig. 5,
E and F). The thickened dermis was also filled
with necrotic acellular areas containing cholesterol clefts (Fig. 5).
The number of hair follicles was remarkably reduced. It is noteworthy
that subcutaneous adipose tissues, which were normally present in mice
with ACAT-1 gene (Fig. 5, A and B), were not
discernible in the hyperlipidemic ACAT-1
/
mice. Measurements of FC
and CE contents of the xathomatous skins showed that FC content was
specifically increased by 5.5-fold in ACAT-1
/
:apoE
/
(20.0 ± 14.8 versus 3.7 ± 1.5 µg/mg tissue; n = 3) and 9.7-fold in ACAT-1
/
:LDLR
/
mice
(31.0 ± 19.6 versus 3.2 ± 1.1 µg/mg tissue;
p < 0.05, n = 3).

View larger version (118K):
[in this window]
[in a new window]
|
Fig. 5.
Histopathology of cutaneous lesions developed
in ACAT-1 / :apo E / and ACAT-1 / :LDLR / mice fed the high
fat diets. 3-month-old mice were used for experiments of high fat
feeding. ACAT-1+/+:apo E / and ACAT-1 / :apo E / mice
were fed high fat diet A for 8 weeks; ACAT-1+/+:LDLR / and
ACAT-1 / :LDLR / mice were fed high fat diet B for 8 weeks.
ACAT-1+/+:apo E / (A) and ACAT-1+/+:LDLR / mice
(B) had normal epidermal and dermal structure with
substantial subcutaneous adipose tissue. No foam cells were observed.
In ACAT-1 / :apo E / (C and D) and
ACAT-1 / :LDLR / mice (D and F), the dermal
layers were extensively infiltrated with fat-laden macrophage (foam
cells). Acellular necrotic areas with cholesterol clefts were present.
There were a reduced number of hair follicles. Note that subcutanous
adipose tissue was not discernible. High magnification of the dermal
layer of ACAT-1 / :apo E / (E) and
ACAT-1 / :LDLR / mice (F) is shown. Many macrophages
exhibited multinucleated giant cell appearance with eosinophilic
cytoplasms.
|
|
Moderate Suppression of Diet-induced Atherosclerosis in ACAT-1
/
Mice Lacking apo E or the LDL Receptor--
After feeding the sets of
apo E and the LDL receptor-deficient mice with high fat diets A and B,
respectively, for 8 weeks, atherosclerotic lesion size was evaluated at
the aortic roots (Fig. 6).
ACAT-1
/
:apo E
/
mice developed a 33% smaller lesion area than
ACAT-1+/+:apo E
/
mice. ACAT-1
/
:LDLR
/
mice had a 53%
reduction in lesion area compared with ACAT-1+/+:LDLR
/
mice. There
were no significant differences in the lesion size between males and
females in each genotype. With regard to the aortic CE contents, 3-fold
and 2-fold decreases were observed in ACAT-1
/
:apo E
/
mice and
ACAT-1
/
:LDLR
/
mice, respectively, as compared with their
ACAT-1+/+ controls (Fig. 7). In contrast to cutaneous xanthomas, aortic FC contents were not increased.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of the inactivation of the ACAT-1
gene on atherosclerotic plaque size. 3-month-old mice were used
for experiments of high fat feeding. Apo E / mice were fed high fat
diet A for 8 weeks, and LDLR / mice were fed high fat diet B for 8 weeks. 10 ACAT-1+/+:apo E / (5 males and 5 females), 10 ACAT-1+/ :apo E / (4 males and 6 females), and 9 ACAT-1 / :apo
E / mice (5 males and 4 females) were fed high fat diet A for 8 weeks. Ten ACAT-1+/+:LDLR / (5 males and 5 females), 9 ACAT-1+/ :LDLR / (4 males and 5 females), and 8 ACAT-1 / :LDLR / mice (3 males and 5 females) were fed high fat
diet B for 8 weeks. Plasma lipoprotein profiles are shown in Table II.
After feeding with the high fat diets for 8 weeks, cross-sectional
lesion areas were evaluated in the aortic roots of the mice. ,
p < 0.05; *, p < 0.01 by analysis of
variance.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 7.
Cholesterol content of the aorta.
3-month-old mice were used for experiments of high fat feeding. Apo
E / mice were fed high fat diet A for 8 weeks, and LDLR / mice
were fed high fat diet B for 8 weeks. Aortas were prepared from the
same animals that were used for the evaluation of atherosclerotic
lesion sizes as shown in Fig. 6. Attached connective tissue and fat
were removed from the aorta as much as possible. Lipids were extracted,
and TC and FC content was measured. CE content was obtained by
subtracting FC from TC. Results for FC and CE are shown in the
upper and lower panels, respectively. There were
significant decreases in the CE content of the aortas from mice lacking
ACAT-1 as compared with those from mice with ACAT-1. ,
p < 0.05; *, p < 0.01; **,
p < 0.001 by analysis of variance.
|
|
 |
DISCUSSION |
In the present study, we have established ACAT-1 null mice and
shown that ACAT-1 is involved in meibomian gland function, xanthoma
formation, and atherosclerosis development in hyperlipidemic mouse
models. Previously, Meiner et al. (11) disrupted the ACAT-1 gene in mice. They reported that their ACAT-1 knockout mice showed significant decreases in cholesterol esterification in embryonic fibroblasts and adrenal membranes. Although these ACAT-1
/
mice had
adrenal lipid depletion and decreased CE content in peritoneal macrophages, the liver retained significant cholesterol esterification activity, suggesting that cholesterol esterification involves more than
one form of esterification enzyme. In addition to confirming Meiner's
original observations, we found that cholesterol esterification in the
epithelium of small intestine is not mediated by ACAT-1. This is in
agreement with the observations that wild-type small intestine
expresses negligible amounts of ACAT-1 (7, 8) and that human intestinal
ACAT activity is largely resistant to immunodepletion with an antibody
against ACAT-1 (32). Recently, three groups independently reported that
a second gene product (ACAT-2) is exclusively expressed in the small
intestine and liver in both nonhuman primates and mice (4-6).
Therefore, ACAT-2 appears to mediate the formation of the CE that is
used for lipoprotein assembly and secretion.
Unexpectedly, we noticed that our ACAT-1
/
mice had altered facial
appearance mainly because of narrow eye fissures (Fig. 2). This
phenotype was noticeable as early as 3 weeks old and had almost
complete penetrance. It can result from either palpebral edema,
brepharoptosis, corneal diseases, impaired sight, reduction in
retro-orbital tissue mass, etc. We found no abnormalities except for
corneal erosion probably because of atrophic meibomian glands (Fig. 2).
Therefore, dysfunction of meibomian glands may account for the narrow
eye fissures. Consistently, ACAT-1 is highly expressed in meibomian
glands (data not shown). The meibomian dysfunction may result from
reduced amounts of CE, increases in FC, or both (Fig. 3). Meibomian
gland dysfunction may cause a decrease in the superficial lipid layer
of tear film, thereby increasing the evaporation of aqueous component
of the tear. This condition is similar to dry eye syndrome in humans
(33). In this context, it is interesting to note that meibomian glands
are modified sebaceous glands which also express high levels of ACAT-1
(8). In addition, we observed atrophic sebaceous glands in ACAT-1
/
mice, but the penetrance of this phenotype was not complete. Atrophy of
sebaceous glands has been reported in cynomolgus monkeys treated with
an ACAT inhibitor, PD 132301-2 (34). Clinically, meibomian and sebaceous glands are commonly affected together; keratoconjunctivitis is frequently associated with sebaceous gland diseases such as seborrhea sicca (35). Further studies will be needed to determine whether abnormal ACAT-1 underlies these diseases.
Jong et al. (36) have recently described cutaneous
abnormalities including atrophy of both sebaceous and meibomian glands in transgenic mice overexpressing apo CI. Because FC is increased in
the skin of the apo CI transgenic mice, the overexpressed apo CI may
inhibit ACAT activities in the glands, thereby producing phenotypes
similar to those of our ACAT-1
/
mice. Phenotypic similarity to the
mutant mouse asebia (ab) was discussed in their paper (37).
Recently, Zheng et al. (38) have reported that the
stearoyl-CoA desaturates 1 (Scd1) gene is disrupted in the ab mice. Because Scd1 catalyzes the formation of
monounsaturated fatty acids, it is tempting to speculate that
cholesterol esterified with monusaturated fatty acids is required for
normal meibomian function. Further studies are needed to clarify this
intriguing issue.
The most outstanding phenotype observed in this study was cutaneous
xanthomatosis with generalized alopecia in the double mutant mice
(Figs. 4 and 5). Hair loss may be secondary to the severe
xanthomatosis; however, the LDL receptor knockout mice fed an
atherogenic diet develop massive xanthomatosis but not alopecia (19).
Therefore, xanthomatosis and alopecia may be independent of each other.
Here again, the alopecia developed in apo CI transgenic mice may be
relevant; apo CI transgenics have atrophic sebaceous glands,
infiltration of inflammatory cells, and a hairless coat (36). Because
ACAT-1 is highly expressed in sebaceous glands (8), it is reasonable to
assume that ACAT-1 deficiency causes atrophy of these glands as it does
in meibomian glands resulting in reduced sebaceous outflow of sebum
onto the skin. Indeed, some, but not all, sebaceous glands showed
atrophic changes in ACAT-1
/
mice (data not shown). There was
massive accumulation of FC in the cutaneous xanthomas, as evidenced
histologically by the presence of cholesterol clefts. Probably, plasma
lipoproteins are taken up by macrophages in which their CE are
hydrolyzed but are not re-esterified because of the absence of ACAT-1.
This may lead to an unlimited increase in cellular FC, which may
eventually result in cell death (39). The presence of giant
multinucleated cells indicates the inflammatory nature of the lesions.
At present, we are unaware of a human disease which parallels this skin
lesion. Common pathogenesis may underlie certain types of non-X
histiocytosis such as xanthoma disseminatum or necrobiotic
xanthogranuloma (40). Absence of subcutaneous fats may reflect the
wasting nature of the disease. Alternatively, the adipose tissue may be
destroyed by infiltrating inflammatory cells.
The effects of ACAT-1 deficiency on atherosclerosis are interesting.
Several ACAT inhibitors reduced plasma lipids by suppressing lipoprotein production in the liver and intestine (41). In addition to
the hypolipemic effects, these compounds are expected to reduce foam
cell formation in atherosclerotic lesions, thereby inhibiting the
progression of atherosclerosis in situ (42). As expected, CE
accumulation was markedly reduced by ACAT-1 disruption in the settings
of both apo E and the LDL receptor deficiency (Fig. 7). However, the
effects on the atherosclerotic lesion size appeared more moderate
compared with those on CE contents. Because Oil-Red-O stains only
neutral lipids, the staining could potentially underestimate the lesion
size in the animals that lacked CE formation. In the setting of apo E
deficiency, the mean cross-sectional lesion size was reduced by 30%.
This anti-atherogenic effect may be accounted for simply by the
reduction of the plasma TC levels, because the plasma TC levels were
reduced by 40% in ACAT-1
/
:apoE
/
mice compared with in
ACAT-1+/+:apoE
/
mice.
In the setting of the LDL receptor deficiency, a similar degree of
suppression in atherosclerotic lesions was observed despite the fact
that the plasma TC levels were not reduced. In this particular model,
it is reasonable to speculate that local inhibition of ACAT activity
results in reduction in atherosclerosis. Therefore, it may be important
to take background clinical condition into account, when treating
atherosclerosis with ACAT inhibitors.
During the preparation of this manuscript, Accad et al. (43)
published a report on atherosclerosis and cutaneous xanthomatosis of
mice lacking both ACAT-1 and either apo E or the LDL receptor. Their
observations are essentially similar to ours; however, they did not
provide quantitative results of the lesion size and CE contents of the
aortas. Instead, they performed more detailed histological analyses of
the lesions and found paucity of macrophage-derived foam cells in the
lesions from mice lacking ACAT-1.
In conclusion, the current study reveals that ACAT-1 is required for
normal meibomian function. Inhibition of ACAT-1 is useful to prevent
the CE accumulation in atherosclerotic lesions that develop in the
hyperlipidemic state. However, exacerbation of xanthomas is a potential
complication of therapy with ACAT inhibitors.
 |
ACKNOWLEDGEMENT |
We thank A. H. Hasty for critical reading
of the manuscript.
 |
FOOTNOTES |
*
This work was supported by a grant-in-aid for scientific
research from the Ministry of Education, Science and Culture, the Promotion of Fundamental Studies in Health Science of The Organization for Pharmaceutical Safety and Research, and Health Sciences Research grants (Research on Human Genome and Gene Therapy) from the Ministry of
Health and Welfare.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
**
Present address: Dept. of Ophthalmology, Yamagata University School
of Medicine, 2-2-2 Iidanishi, Yamagata, Yamagata 990-9585, Japan.

Present address: Metabolism, Endocrinology, and
Atherosclerosis, Inst. of Clinical Medicine, University of Tsukuba,
1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
§§
To whom correspondence should be addressed: Dept. of Metabolic
Diseases, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Tel.: 81-3-3815-5411 (ext. 33113); Fax: 81-3-5802-2955; E-mail: ishibash-tky@umin.ac.jp.
Published, JBC Papers in Press, April 20, 2000, DOI 10.1074/jbc.M002541200
 |
ABBREVIATIONS |
The abbreviations used are:
ACAT, Acyl-CoA:cholesterol acyltransferase;
apo, apolipoprotein;
LDL, low
density lipoprotein;
LDLR, LDL receptor;
HPLC, high performance liquid
chromatography;
TC, total cholesterol;
TG, triglycerides;
FC, free
cholesterol;
CE, cholesteryl esters;
HDL-C, cholesterol contents in
high density lipoprotein fraction;
kb, kilobase(s).
 |
REFERENCES |
| 1.
|
Goodman, D. S.
(1965)
Physiol. Rev.
45,
747-839
|
| 2.
|
Suckling, K. E.,
and Stange, E. F.
(1985)
J. Lipid. Res.
26,
647-671
|
| 3.
|
Chang, C. C.,
Huh, H. Y.,
Cadigan, K. M.,
and Chang, T. Y.
(1993)
J. Biol. Chem.
268,
20747-20755
|
| 4.
|
Anderson, R. A.,
Joyce, C.,
Davis, M.,
Reagan, J. W.,
Clark, M.,
Shelness, G. S.,
and Rudel, L. L.
(1998)
J. Biol. Chem.
273,
26747-26754
|
| 5.
|
Cases, S.,
Novak, S.,
Zheng, Y. W.,
Myers, H. M.,
Lear, S. R.,
Sande, E.,
Welch, C. B.,
Lusis, A. J.,
Spencer, T. A.,
Krause, B. R.,
Erickson, S. K.,
and Farese, R. V., Jr.
(1998)
J. Biol. Chem.
273,
26755-26764
|
| 6.
|
Oelkers, P.,
Behari, A.,
Cromley, D.,
Billheimer, J. T.,
and Sturley, S. L.
(1998)
J. Biol. Chem.
273,
26765-26771
|
| 7.
|
Uelmen, P. J.,
Oka, K.,
Sullivan, M.,
Chang, C. C. Y.,
Chang, T. Y.,
and Chan, L.
(1995)
J. Biol. Chem.
270,
26192-26201
|
| 8.
|
Meiner, V.,
Tam, C.,
Gunn, M. D.,
Dong, L. M.,
Weisgraber, K. H.,
Novak, S.,
Myers, H. M.,
Erickson, S. K.,
and Farese, R. V., Jr.
(1997)
J. Lipid. Res.
38,
1928-1933
|
| 9.
|
Chang, T. Y.,
Chang, C. C.,
and Cheng, D.
(1997)
Annu. Rev. Biochem.
66,
613-638
|
| 10.
|
Miyazaki, A.,
Sakashita, N.,
Lee, O.,
Takahashi, K.,
Horiuchi, S.,
Hakamata, H.,
Morganelli, P. M.,
Chang, C. C.,
and Chang, T. Y.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
1568-1574
|
| 11.
|
Meiner, V. L.,
Cases, S.,
Myers, H. M.,
Sande, E. R.,
Bellosta, S.,
Schambelan, M.,
Pitas, R. E.,
McGuire, J.,
Herz, J.,
and Farese, R. V., Jr.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14041-14046
|
| 12.
|
Joyce, C.,
Skinner, K.,
Anderson, R. A.,
and Rudel, L. L.
(1999)
Curr. Opin. Lipidol.
10,
89-95
|
| 13.
|
Cao, G.,
Goldstein, J. L.,
and Brown, M. S.
(1996)
J. Biol. Chem.
271,
14642-14648
|
| 14.
|
Zhang, S. H.,
Reddick, R. L.,
Piedrahita, J. A.,
and Maeda, N.
(1992)
Science
258,
468-471
|
| 15.
|
Ishibashi, S.,
Brown, M. S.,
Goldstein, J. L.,
Gerard, R. D.,
Hammer, R. E.,
and Herz, J.
(1993)
J. Clin. Invest.
92,
883-893
|
| 16.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 17.
|
Yagyu, H.,
Ishibashi, S.,
Chen, Z.,
Osuga, J.,
Okazaki, M.,
Perrey, S.,
Kitamine, T.,
Shimada, M.,
Ohashi, K.,
Harada, K.,
Shionoiri, F.,
Yahagi, N.,
Gotoda, T.,
Yazaki, Y.,
and Yamada, N.
(1999)
J. Lipid. Res.
40,
1677-1685
|
| 18.
|
Paigen, B.,
Morrow, A.,
Brandon, C.,
Mitchell, D.,
and Holmes, P.
(1985)
Atherosclerosis
57,
65-73
|
| 19.
|
Ishibashi, S.,
Goldstein, J. L.,
Brown, M. S.,
Herz, J.,
and Burns, D. K.
(1994)
J. Clin. Invest.
93,
1885-1893
|
| 20.
|
Osuga, J.,
Inaba, T.,
Harada, K.,
Yagyu, H.,
Shimada, M.,
Yazaki, Y.,
Yamada, N.,
and Ishibashi, S.
(1995)
Biochem. Biophys. Res. Commun.
214,
653-662
|
| 21.
|
Tozawa, R.,
Ishibashi, S.,
Osuga, J.,
Yagyu, H.,
Oka, T.,
Chen, Z.,
Ohashi, K.,
Perrey, S.,
Shionoiri, F.,
Yahagi, N.,
Harada, K.,
Gotoda, T.,
Yazaki, Y.,
and Yamada, N.
(1999)
J. Biol. Chem.
274,
30843-30848
|
| 22.
|
Li, B.-L.,
Li, X.-L.,
Duan, Z.-J.,
Lee, O.,
Lin, S.,
Ma, Z.-M.,
Chang, C. C. Y.,
Yang, X.-Y.,
Park, J. P.,
Mohandas, T. K.,
Noll, W.,
Chan, L.,
and Chang, T.-Y.
(1999)
J. Biol. Chem.
274,
11060-11071
|
| 23.
|
Lin, S.,
Cheng, D.,
Liu, M.-S.,
Chen, J.,
and Chang, T.-Y.
(1999)
J. Biol. Chem.
274,
23276-23285
|
| 24.
|
Fujimura, K.,
Ise, N.,
Ueno, E.,
Hori, T.,
Fujii, N.,
and Okada, M.
(1997)
J. Clin. Lab. Anal.
11,
315-322
|
| 25.
|
Harlow, E.,
and Lane, D.
(1988)
Antibodies: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 26.
|
Folch, J.,
Lees, M.,
and Sloane Stanley, G. A.
(1957)
J. Biol. Chem.
226,
497-509
|
| 27.
|
Heider, J.,
and Boyett, R. L.
(1978)
J. Lipid. Res.
19,
514-518
|
| 28.
|
Billheimer, J. T.,
Tavani, D.,
and Nes, W. R.
(1981)
Anal. Biochem.
111,
331-335
|
| 29.
|
Becker, A.,
Bottcher, A.,
Lackner, K. J.,
Fehringer, P.,
Notka, F.,
Aslanidis, C.,
and Schmitz, G.
(1994)
Arterioscler. Thromb.
14,
1346-1355
|
| 30.
|
Paigen, B.,
Morrow, A.,
Holmes, P. A.,
Mitchell, D.,
and Williams, R. A.
(1987)
Atherosclerosis
68,
231-240
|
| 31.
|
Shimada, M.,
Ishibashi, S.,
Inaba, T.,
Yagyu, H.,
Harada, K.,
Osuga, J.-I.,
Ohashi, K.,
Yazaki, Y.,
and Yamada, N.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7242-7246
|
| 32.
|
Lee, O.,
Chang, C. C.,
Lee, W.,
and Chang, T. Y.
(1998)
J. Lipid. Res.
39,
1722-1727
|
| 33.
|
Lemp, M. A.,
and Wolfley, D. E.
(1992)
in
Adler's Physiology of the Eye
(Hart, W. M., ed)
, pp. 18-28, Mosby, St. Louis, MO
|
| 34.
|
Reindel, J. F.,
Dominick, M. A.,
Bocan, T. M.,
Gough, A. W.,
and McGuire, E. J.
(1994)
Toxicol. Pathol.
22,
510-518
|
| 35.
|
McCulley, J. P.,
and Sciallis, G. F.
(1977)
Am. J. Ophthalmol.
84,
788-793
|
| 36.
|
Jong, M. C.,
Gijbels, M. J.,
Dahlmans, V. E.,
Gorp, P. J.,
Koopman, S. J.,
Ponec, M.,
Hofker, M. H.,
and Havekes, L. M.
(1998)
J. Clin. Invest.
101,
145-152
|
| 37.
|
Gates, A. H.,
and Karasek, M. A.
(1965)
Science
148,
1471-1473
|
| 38.
|
Zheng, Y.,
Eilertsen, K. J.,
Ge, L.,
Zhang, L.,
Sundberg, J. P.,
Prouty, S. M.,
Stenn, K. S.,
and Parimoo, S.
(1999)
Nat. Genet.
23,
268-270
|
| 39.
|
Tabas, I.
(1997)
Trends Cardiovasc. Med.
7,
256-263
|
| 40.
|
Burgdorf, W. H. C.
(1998)
in
Lever's Histopathology of the Skin
(Elder, D.
, Elenitsas, R.
, Javorsky, C.
, and Johnson, B., Jr., eds), 8th Ed.
, pp. 591-616, Lippencott-Raven Publishers, Philadelphia, PA
|
| 41.
|
Krause, B. R.,
and Bocan, T. M. A.
(1995)
in
ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-atherosclerotic Activities in Experimental Animals
(Ruffolo, R. R., Jr.
, and Hollinger, M. A., eds)
, CRC Press, Boca Raton, FL
|
| 42.
|
Bocan, T. M.,
Mueller, S. B.,
Uhlendorf, P. D.,
Newton, R. S.,
and Krause, B. R.
(1991)
Arterioscler. Thromb.
11,
1830-1843
|
| 43.
|
Accad, M.,
Smith, S. J.,
Newland, D. L.,
Sanan, D. A.,
King, L. E., Jr.,
Linton, M. F.,
Fazio, S.,
and Farese, R. V., Jr.
(2000)
J. Clin. Invest.
105,
711-719
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Okazaki, M. Igarashi, M. Nishi, M. Sekiya, M. Tajima, S. Takase, M. Takanashi, K. Ohta, Y. Tamura, S. Okazaki, et al.
Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages
J. Biol. Chem.,
November 28, 2008;
283(48):
33357 - 33364.
[Abstract]
[Full Text]
[PDF]
|
 |
|